GERON CORP Interest Payable
GERON CORP (GERN) had Interest Payable of $7.26 million as of 2024-09-30, per its 10-Q filed 2024-11-07.
Financial Statements › Balance Sheet › Liabilities
us-gaap:InterestPayableCurrentAndNoncurrent · last filed 2024-11-07
- 2024-09-30: Interest Payable $7.26M.
- 2024-06-30: Interest Payable $10.19M.
- 2024-03-31: Interest Payable $7.59M.
- 2023-12-31: Interest Payable $10.09M.
| Period end | Interest Payable |
|---|---|
| 2024-09-30 | $7.26M 10-Q · filed 2024-11-07 |
| 2024-06-30 | $10.19M 10-Q · filed 2024-08-08 |
| 2024-03-31 | $7.59M 10-Q · filed 2024-05-02 |
| 2023-12-31 | $10.09M 10-K · filed 2024-02-28 |
| 2023-09-30 | $7.94M 10-Q · filed 2023-11-02 |
| 2023-06-30 | $9.59M 10-Q · filed 2023-08-03 |
| 2023-03-31 | $11.17M 10-Q · filed 2023-05-11 |
| 2022-12-31 | $7.73M 10-K · filed 2023-03-16 |
| 2022-09-30 | $8.49M 10-Q · filed 2022-11-07 |
| 2022-06-30 | $8.76M 10-Q · filed 2022-08-11 |
| 2022-03-31 | $8.89M 10-Q · filed 2022-05-09 |
| 2021-12-31 | $9.73M 10-K · filed 2022-03-10 |
| 2021-09-30 | $6.89M 10-Q · filed 2021-11-09 |
| 2021-06-30 | $7.66M 10-Q · filed 2021-08-16 |
| 2020-12-31 | $6.63M 10-K · filed 2021-03-11 |
| 2020-09-30 | $7.02M 10-Q · filed 2020-11-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B |